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ABSTRACT 
The withdrawal syndrome in alcohol-dependent patients appears to be a major stressful event 
whose intensity increases with repetition of detoxifications according to a kindling process. 
Disturbances in the balance between excitatory and inhibitory neural processes are reflected in 
a perturbed physical state while disturbances in the balance between positive and negative 
reinforcements are reflected in a perturbed mood state. Our purpose is to link the different 
behavioral outcomes occurring during withdrawal with specific biological brain mechanisms 
from the animal to the human being. Better understanding of the various biological mechanisms 
underlying withdrawal from alcohol will be the key to design and to apply appropriate 
pharmaceutical management, together with appropriate therapy aimed at inducing protracted 
abstinence. 
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Dependence and withdrawal 
Withdrawal stands at the core of alcohol dependence. A large body of literature has stated that 
no real alcohol dependence occurs without withdrawal signs. 
Withdrawal signs appear within hours of cessation of alcohol intake. They are associated with a 
negative mood state including anxiety and tension. Alcohol may thus act as a negative 
reinforcement, as animals and humans beings will tend to avoid environments and behaviors 
inducing this negative state. At this stage alcohol intake is able to suppress and may even 
prevent the occurrence of the physical and mood disturbances. Alcohol and related components 
will therefore be perceived as highly attractive and will represent a potentially powerful 
reinforcement. Animals and humans will seek environments and develop behaviors aiming at 
the intake of alcohol. 
These synergic negative and positive effects produced by alcohol give rise to withdrawal and 
protracted withdrawal, a pivotal role in the way out of alcoholism. 
Animal studies may provide useful biological insights for a better understanding of human 
alcohol withdrawal. 
During alcohol dependence, neuroadaptations within the central nervous system (CNS) occur 
allowing the brain to function regularly while being disturbed by alcohol. Ethanol is not a 
molecule with a single clear effect on a particular neurotransmitter system but it may affect 
multiple stages of the neurotransmission cascade of the large majority of neurotransmitters. 
Our major goal is not to precisely describe the modifications at the different levels of the 
neurotransmitters, neuromodulators and neurohormones, but rather to define the occurrence of 
drinking according to the intensity of the physical signs and the mood state induced by 
withdrawal. When alcohol intake is arrested, CNS changes are by far the main source of signs 
and symptoms of adjustment of physical and mood state. Physical state is the reflection of a 
brain homeostatic balance between excitatory and inhibitory mechanisms while mood state 
depends on a hedonic balance leading to positive and negative reinforcements. 
BRAIN HOMEOSTASIS 
Cessation of chronic alcoholization leads the brain to an overexcited state observed through 
signs such as tremor and sometimes seizures. 
This overexcitement is due to increase in glutamate transmission (a major neuroexcitatory 
amino acid) combined with an altered GABAA transmission (a major neuroinhibitory pathway). 
Recent microdialysis studies showed that ethanol withdrawal was associated with increase in 
glutamate in the striatum [1], the nucleus accumbens (NAC) [2] and hippocampus [3]. Human 
studies have indicated that excitatory neurotransmitters were elevated in the CSF of alcohol-
dependent patients [4]. Changes in GABAA receptors subunits (particularly α1 – 5 and β2 – 3) 
reduce the inhibitory activity of GABA contributing to hyperexcitability of neurons [5]. 
Moreover, intermittent withdrawal is also accompanied by an increase in aspartate (a 
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neuroexcitatory amino acid) and modification in GABAA α4 subunit, probably leading to a 
‘kindled overexcitation’ [6,7]. 
The neural activity modulated by both excitatory and inhibitory influences are dependent on the 
influx of calcium into the cells through receptor-operated calcium channels and voltage 
operating channels. A general adaptive increase in these channels is observed during tolerance 
and withdrawal leading to generalized neuronal excitability induced by calcium entry [8,9]. 
Adenosine can also function as an inhibitory modulator of seizure activity. Adenosine A1 
receptors are upregulated during ethanol withdrawal and repeated ethanol withdrawals [10]. 
This likely represents an adaptive response to seizure severity induced by repeated episodes of 
withdrawal. 
Adenosine alters the responding levels of second messengers (like cyclic adenosine 
monophosphate, protein phosphatase, protein kinase A and C) allowing information to be 
transmitted more or less effectively to the connected neurons. Blockade of adenosine activity 
can reduce the occurrence of seizures at the cessation of chronic ethanol intake [11] without 
affecting ethanol consumption [12]. 
Alcohol intake is always able to rapidly abolish the negative reinforcement induced by its 
withdrawal and it would thus appear as a powerful medication against physical perturbations. 
Other classical neurotransmitters also mediate physical signs of alcohol withdrawal but to a 
lower extent, since agonists and antagonists of monoamines modify in a limited extend to those 
physical signs [13,14]. 
HEDONIC HOMEOSTASIS 
Withdrawal from alcohol leads to a state inducing increase of dysphoria, anxiety, negative 
emotional state and stress probably because of a decrease in dopamine (DA) release in the NAC. 
The symptoms can be easily alleviated by alcohol intake. This may be related to an increase of 
DA activity in the NAC, as observed in rats where self-administered alcohol during withdrawal 
was able to rapidly reverse the deficit in DA and serotonin in the NAC [15]. 
DA is the major neurotransmitter released during attracted stimuli (including drugs), 
particularly in the NAC. Even anticipation of reward (but not punishment) leads to DA release in 
the NAC [16]. Among various modifications in neurotransmission after alcohol cessation, an 
increase in acetylcholine (ACHe) was observed in hippocampal microdialysate following the 
same timing of the deficit in DA accumbal release [17]. In parallel to the putative role of DA in 
positive reinforcement, ACHe may play a major role in the negative reinforcement [18]. 
The endogenous opioid system also indirectly activates the mesolimbic dopaminergic system 
and particularly the opioid receptor may modulate this dopaminergic deficit during alcohol 
withdrawal [19]. 
Withdrawal represents a major source of stress and the limbic system will immediately answer 
by secreting corticotropin-releasing factor (CRF) [20]. The limbic system is a large complex of 
brain structures regulating emotional processes. It plays a role in the negative reinforcement 
induced by withdrawal. Direct CRF antagonist injection into limbic areas were able to block 
anxiogenic-like responses induced by withdrawal [21]. CRF R1 or R2 receptors deficient 
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knockout mices present opposite impairments in anxiety-like (estimated by open-field test and 
light-dark test) and memory disorders. They also show opposite activity profiles during 
withdrawal signs [22]. CRF R1 receptors are directly activated in alcohol withdrawal and lead to 
anxiogenic-like responses. The time schedule of the CRF release in the amygdala observed 
during alcohol withdrawal is long lasting (peak value around 12 h after onset of withdrawal) as 
compared to conventional restraint stress (return to baseline CRF after 1 h) [21]. CRF in 
cerebrospinal fluid is also elevated during withdrawal in alcohol patients [23] and protracted 
abstinence enhances neuronal sensitivity to CRF in rats (estimated by EEG and event-related 
potentials) 15 weeks after complete withdrawal [24]. This long lasting increase in sensitivity to 
CRF may induce increased sensitivity to daily environmental stresses and thus may lead to 
secondary conditioned reinforcement. 
During such conditioning, environmental stimuli or internal stimuli associated with withdrawal 
can act as cues for the appearance or exacerbation of the neurochemical modifications leading to 
a kindling process. 
A common trait emerging when analyzing the neurochemical changes appearing during physical 
and mood state withdrawal modifications, is that alcohol intake leads to the immediate 
abolishment of undesirable symptoms. With conditioned secondary reinforcement and the 
kindling process associated with repeated withdrawals, self-administration of alcohol will 
progressively increase and will stabilize at a higher level [25]. 
Alcohol withdrawal syndrome 
The alcohol withdrawal syndrome is a complex set of symptoms occurring in alcohol dependent 
patients after alcohol cessation. It involves a wide range of brain neurotransmitters implicated 
in the development of alcohol tolerance and reflects a homeostatic readjustment of the CNS [26]. 
The signs and symptoms of alcohol withdrawal syndrome have been well described in humans. 
They can be divided into three sets although many classifications have been made for various 
purposes [27]. In the first hours following the last alcohol intake, sympathetic hyperactivity is 
responsible for tachycardia, sweating, tremor, hypertension, anxiety and agitation that usually 
peak within 24 h. Later on (24 – 48 h after alcohol cessation), epileptic seizures may occur, 
whereas delirium tremens can be observed from 3 to 7 days after acute abstinence. This third 
set of symptoms is characterized by auditory and visual hallucinations, confusion and 
disorientation, clouding of consciousness and pronounced autonomic hyperactivity. It can lead 
to death from respiratory and cardiovascular collapse [28]. All these symptoms are disabling 
enough to lead many patients to resume alcohol consumption at the early stages of withdrawal. 
The severity of alcohol withdrawal syndrome is therefore a major risk factor of early relapse 
[29]. The understanding of its complex pathophysiology may help finding effective tools in 
preventing such an event. 
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As mentioned above, among the many neurotransmitters involved in alcohol withdrawal, DA 
seems to play a central role both in tolerance to and withdrawal from alcohol. Alcohol activates 
the mesolimbic dopamine system by releasing DA in the NAC and it has been hypothesized that 
subjects with impaired dopaminergic activity may compensate for this deficiency by the use of 
alcohol and other substances that increase brain DA levels [30,31]. Both neuroendocrine [32] 
and genetic studies [33] have highlighted the implication of a reduced DAD2 receptor (DRD2) 
functioning in severe alcohol dependence. Whether this deficiency plays a role in some of the 
symptoms observed during withdrawal is still controversial, but the hypothesis of a reduced 
dopaminergic activity in the mesocorticolimbic reward pathway, responsible for negative mood 
states after alcohol cessation remains attractive [34]. Indeed, it has been shown that alcoholic 
patients carrying the A1 allele of the DRD2 gene exhibit lower densities of postsynaptic D2-
receptors [35,36], which may result in low DA neurotransmission. These patients displayed 
increased depressive symptoms during acute alcohol withdrawal [37]. Poor dopaminergic 
functioning during the early stages of withdrawal and consecutive depressive symptoms could 
also be linked to higher recoveries in dopamine transporter (DAT) density in some alcoholic 
patients shortly after alcohol cessation [38]. It has been shown that this protein, which seems to 
be decreased during prolonged heavy drinking [39], reuptakes DA into presynaptic terminals 
and thereby terminates dopaminergic activity in synaptic neurotransmission [40]. This is in 
accordance with a reported increase of DAT levels in depressed patients [41]. However, opposite 
fi concerning DA availability and its clinical consequences have been reported. Many reports 
suggest a DA overactivity during alcohol withdrawal, which may be linked to decreased 
GABAergic neurotransmission. It has been shown that GABAergic neurons directly inhibit 
dopaminergic neurons in the substantia nigra [42]. Therefore reduced GABAergic activity, as 
observed during alcohol withdrawal, leads to enhanced dopaminergic transmission, which could 
be responsible for more severe withdrawal symptoms [43]. This is in accordance with many 
studies showing higher concentrations of the DA metabolite homovanillic acid in alcoholics with 
delirium compared to patients who did not suffer from clouding of consciousness [44]. 
Furthermore, insufficient clearance of DA in the synaptic cleft leading to hyperdopaminergic 
states may be related to severe withdrawal symptoms [45], as suggested by the higher risk of 
seizures or delirium during withdrawal in patients carrying the A9 allele of the DAT-gene 
[40][46]. The functional consequence of the presence of this allele could indeed induce an 
alteration in DAT-gene expression [47] resulting in lower DA reuptake. 
In summary, dopaminergic neurotransmission may be responsible for various symptoms of the 
alcohol withdrawal syndrome. Dopaminergic hypoactivity may cause dysphoric features while 
its overactivity could induce hallucinations. This can be paralleled to the putative 
pathophysiological mechanisms underlying psychotic symptomatology in which subcortical 
mesolimbic rewarding DA projections and mesocortical cognitive projections seem to interact in 
opposite ways, roughly underlying negative symptoms on the one hand, and positive on the 
other hand [48]. 
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As for the serotonergic system, it has been demonstrated that serotonin (5-HT) could play a 
facilitator role on DA release in the NAC [49,50] while ethanol seems to directly stimulate the 
release of DA and 5-HT [51]. This could lead to a deficiency in the release of these 
neurotransmitters during ethanol withdrawal. Furthermore, interactions between impaired 
serotonergic neurotransmission and anxiety and depression have been postulated. As a 5-HT 
deficiency seems to be involved in alcohol dependence as well as in the maintenance of excessive 
alcohol consumption [52 – 54], it could be expected to influence the occurrence of mood 
symptoms in alcoholics, especially during withdrawal. This hypothesis was tested in alcohol-
dependant rats, suggesting that deficits in accumbal 5-HT release may contribute to the negative 
affective consequences of alcohol withdrawal and motivate ethanol-seeking behavior [15]. 
In human, a significant reduction in the availability of 5- HT transporters was found in the raphe 
nuclei area of recently detoxified alcoholics, which was strongly correlated with increased levels 
of anxiety and depression during early abstinence [55]. Furthermore, reduced transcriptional 
efficiency of the serotonin transporter (5HTT) may underlie another set of symptoms during 
alcohol withdrawal. The frequency of the short allele of the polymorphism coding for 5HTT, 
responsible for modifications in 5-HT activity [56] was indeed strongly increased in alcoholics 
who reported seizures or delirium including hallucinations [47]. 
Finally, it has been postulated that deficiency of brain 5- HT activity in alcoholics may result in a 
decreased impulse-control over drug taking [57], particularly during alcohol withdrawal. 
According to Cloninger’s typology [58], this may lead to increased craving and anxiety during 
withdrawal, particularly in type II alcoholics, who are supposed to have low cerebrospinal fluid 
levels of 5-HT and its metabolite 5-HIAA, as opposed to late-alcoholism-onset-type I subjects 
[59]. Behavioral differences between type I and type II alcoholics were also observed by George 
et al. [60] who, after a m-chlorophenylpiperazine (m-CPP) challenge test, linked this finding to a 
hypo-5-HT2C receptor function. 
NORADRENERGIC SYSTEM 
Finally, attention should also be focused on another neurotransmitter involved in the 
pathophysiology of alcohol withdrawal, namely noradrenaline. An important aspect of 
withdrawal is increased central excitation, which leads to a sympathetic overactivity. Plasma 
and cerebrospinal fluid levels of noradrenaline are increased because of the overstimulation 
of noradrenergic neurons by the increased glutamate transmission and the loss of 
noradrenergic autoinhibition by reduced postsynaptic a2-adrenoreceptor function [61]. 
Many studies have reported a persistent hypo-a2-adrenoreceptor functioning during and 
after withdrawal as assessed by a blunted growth hormone (GH) response to clonidine [62 – 
64]. GH response to clonidine is also known to be impaired in endogenous depression [65,66] 
as well as in panic disorder [67,68]. Impaired a2-adrenoreceptor function might therefore 
be hypothesized to be responsible for anxiety and depressive symptoms occurring during 
alcohol withdrawal. However, no evidence for a relationship between dysphoric features and 
a2-adrenoreceptor subsensitivity has been found to date [69]. Alternatively, the noradrenergic 
overdrive observed in alcohol withdrawal may solely be implicated in autonomic symptoms 
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such as tachycardia, hypertension, tremor and sweating. As mentioned above, alcohol 
withdrawal reflects altered function of the brain processes involved in the development of 
tolerance to alcohol. In particular, impaired balance between inhibitory functions and excitatory 
systems seems to be implicated in the occurrence of some of the symptoms observed during 
acute withdrawal. On the one hand, chronic alcohol consumption enhances g-aminobutyric 
acid (GABA) inhibitory action, while on the other hand, it blocks some of the brain excitatory 
systems such as the glutamate N-methyl-D-aspartate (NMDA) receptor. The increase in the 
number of these receptors observed during chronic alcohol intoxication, has been interpreted 
as an attempt by the brain to compensate for diminished glutamate transmission [26]. 
Thus, when alcohol is acutely removed, GABA receptors are no longer stimulated while NMDA 
function is excessive. The latter is also due to the magnesium depletion observed in chronic 
alcoholism [70]. NMDA overactivity seems, among other pathways, to induce noradrenaline 
release, and may therefore contribute to the increased sympathetic activity observed during 
withdrawal. (cf. Table 1) 
Table 1. Putative relationships between neurotransmitters disturbances and alcohol withdrawal 
symptoms 
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Alcohol withdrawal syndrome as a stressor 
When managed in a medical setting, the severity of the symptoms and signs of withdrawal in 
alcohol-dependent patients is usually maximal on the first day of abstinence, and then decreases 
over a period of 5 – 7 days. 
In the search for neurobiological markers of the syndrome, it has been shown that acute alcohol 
withdrawal is associated with hypercortisolaemia [71 – 75] and increase of salivary cortisol 
levels [76]. The magnitude of cortisol increase was related to the severity of withdrawal 
symptoms. The mechanism of hypercortisolaemia during alcohol withdrawal remains unclear. It 
does not appear to be due to hypothalamo-pituitary-adrenal axis hyperactivity since plasma 
ACTH concentration is decreased at baseline [72] and after injection of corticotrophin-releasing 
hormone [77,78]. 
Biochemical studies indicate that increased plasma levels of norepinephrine are associated with 
certain symptoms of alcohol withdrawal like blood pressure and heart rate response to standing 
[79] and that the severity of the withdrawal syndrome correlates positively with the amount of 
released norepinephrine [80,81]. 
In addition to medullo-adrenal and sympathetic hyperactivity, there are also indications of 
central adrenergic hypersecretion during alcohol withdrawal. High concentrations of 
norepinephrine and its major metabolite 3-methoxy-4-hydroxyphenylglycol (MOPEG) have been 
reported in cerebrospinal fluid in alcohol withdrawn patients [82,83]. In the beginning of the 
withdrawal manifestations, there is a positive correlation between MOPEG levels and sleeping 
problems, tremors, restlessness, visual hallucinations and elevated muscle tension [84]. 
These converging observations that alcohol withdrawal syndrome is a powerful stressor could 
be of major importance for the understanding of the development of addiction. It has become 
clear that administration of addictive drugs to laboratory rats can cause time-dependent 
sensitization that is probably a function of their nonspecific, stressful nature [85]. This is 
underlined by the fact that there is cross-sensitization between a stress challenge after previous 
drug administration [86] and a drug challenge after a previous stressful experience [87]. 
Repeated intracerebroventricular administration of CRF has similar sensitizing effects on later 
responsivity to amphetamine [88]. Stressful experiences in humans can result in a spectrum of 
long-term changes in behavioral, autonomic and hormonal responsivity. An extreme form of 
such alterations is found in patients with post-traumatic stress disorder. A number of animal 
models has been developed in which intense stressful experiences (such as shocks or social 
confrontations) result in long-term altered responsivity of behavioral, autonomic and hormonal 
responses to aversive challenges [89]. 
Daily exposure to emotional stress enhances the initiation of self-administration of morphine 
and cocaine, and ventral tegmental intracranial electrical self-stimulation in rats [90,91]. 
Moreover, social defeat directly followed by threat for four consecutive days increases the 
amount of cocaine self-administration and defeated rats acquire cocaine self-administration in 
approximately half the time of non-defeated rats [92,93]. These studies suggest that certain 
types of stress can enhance the addictive properties of drugs, possibly by enhancing the 
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sensitivity of the mesocorticolimbic dopaminergic system to these substances. Conversely, drug-
induced sensitization of the mesocorticolimbic DA system may underlie increased 
responsiveness to stress. 
Therefore, we hypothesize that drug withdrawal syndrome and especially alcohol withdrawal 
syndrome could be one important factor contributing to the progressive reinforcement of 
drinking through the progressive sensitization of the brain reward system by stress hormones. 
This could also be responsible for the higher risk to develop dependence to other drugs in 
alcoholics. 
Such a sensitization to alcohol withdrawal is in accordance with the kindling hypothesis of 
alcohol withdrawal stated by Ballenger and Post [94]. This hypothesis has recently gained 
considerable support. Indeed, clinical studies have demonstrated a positive relationship 
between the number of previous withdrawal reactions and the risk of developing seizures 
during oncoming withdrawal reactions [95,96, Verbanck et al., unpublished]. 
These findings are in agreement with animal studies showing increased withdrawal behavior 
during repeated episodes of alcohol intoxication and withdrawal [97 – 99]. This process can be 
prevented by blocking the early withdrawal reactions with phenobarbital or diazepam 
[100,101], even if diazepam was reported to be unable to prevent the occurrence of seizures 
[102]. 
Alcohol withdrawal as a neurotoxic event 
Acute effects of ethanol disrupt glutamatergic neurotransmission by reducing the sensitivity of 
the NMDA receptor [103]. Prolonged inhibition of NMDA receptors by ethanol induces their 
upregulation. When chronic alcohol consumption ceased, the upregulation combined with an 
increased release of excitatory amino acids can result in acute excitotoxicity [4]. Neurobiological 
effects of alcohol on the brain, such as intoxication, withdrawal symptoms and Wernicke– 
Korsakoff syndrome can be understood as consequences of effects of ethanol on the 
glutamatergic system. 
Specifically, it was demonstrated that ethanol withdrawal is associated with increased 
extracellular glutamate [1]. This increase in release of glutamate could have major long-term 
consequences for the alcoholic patient. There is evidence of specific alcohol-associated frontal 
lobe injury [104]. While alcohol-induced oxidative stress may cause global brain impairment, the 
frontal lobes can be specifically injured by glutamate-mediated excitotoxicity because frontal 
lobes are particularly rich in excitatory amino acid pathways [105]. Using neuropsychological 
and radioisotopical methods, we demonstrated recently that frontal lobe hypometabolism in 
detoxified alcoholics induces specifically a major impairment of executive functions [106,107]. 
We also demonstrated that this impairment of executive functions (decision-making, flexibility, 
double-task) is a major clinical issue because it contributes dramatically to the risk of short-term 
relapse after detoxification [108]. 
The withdrawal syndrome in alcohol-dependent patients appears to be a major stressful event 
whose intensity increases with repetition of detoxifications according to a kindling process. 
These phenomena could be at least partly responsible for a progressive increase of the 
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reinforcing power of addictive drugs including alcohol, and for brain damage through an 
excitotoxic mechanism due to an increasing release of excitatory amino acids during withdrawal. 
Progressive neurotoxic lesions due to excitotoxicity in the frontal lobe could be a major 
consequence of repeated alcohol withdrawal, with major neuropsychological deficits negatively 
influencing the outcome after detoxification. 
Hippocampus, another neural structure rich in excitatory amino acids projections, also appears 
to be particularly sensitive to the neurotoxic effects ethanol administration [109,110], especially 
after intermittent exposure [111,112]. This was demonstrated to result in memory impairments 
in rats [113]. Hippocampus lesions seem to be due to both excitoxicity [114,115] and 
glucocorticoids [116 – 120]. A more recent drug, acamprosate, appears to have promising 
neuroprotective properties against the consequences of multiple withdrawals in animal models 
[121]. 
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